RGS4 inhibits glioma cells sensitivity to radiotherapy and temozolomide by regulating ferroptosis
A three-gene signature was developed in a risk-score model, which could be used to predict the prognosis of glioma patients. RGS4 is dysregulated in many types of cancers, and is a candidate prognostic biomarker for many types of cancers. Moreover, RGS4 may be a target for predicting and enhancing the chemoradiotherapy sensitivity of gliomas.
Authors
- Yizhi Ge (ORCID: https://orcid.org/0000-0001-8349-0970)
- Wenxuan Huang (ORCID: https://orcid.org/0009-0009-5813-9471)
- Dan Zong (ORCID: https://orcid.org/0000-0003-4984-4557)
- Chunfa Qian
- Huanfeng Zhu
- Hao Zhang (ORCID: https://orcid.org/0009-0006-9483-834X)
Institutions
- Nanjing Brain Hospital (CN)
- Jiangsu Cancer Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- International Journal of Neuroscience
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1080/00207454.2024.2401661
- Citations
- 2
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.84